Multiple Sclerosis and Related Disorders

The gut microbiome in relapsing versus progressive multiple sclerosis 1:56
The gut microbiome in relapsing versus progressive multiple sclerosis
Daiki Takewaki • 28 Feb 2022
The central vein sign: a novel imaging biomarker for MS diagnosis 1:05
The central vein sign: a novel imaging biomarker for MS diagnosis
Pascal Sati • 26 Feb 2022
Clinical validation of the MSDA test 1:52
Clinical validation of the MSDA test
Ferhan Qureshi • 24 Feb 2022
How does tDCS work in MS? 1:00
How does tDCS work in MS?
Leigh Charvet • 26 Feb 2022
Latest clinical trials and updates on the relationship between sex hormones and MS 4:05
Latest clinical trials and updates on the relationship between sex hormones and MS
Burcu Zeydan • 24 Feb 2022
Targeting remyelination through oligodendrocyte differentiation in MS 1:22
Targeting remyelination through oligodendrocyte differentiation in MS
Jason Plemel • 25 Feb 2022
Socio-scientific issues facing MS treatment in Latin America 1:41
Socio-scientific issues facing MS treatment in Latin America
Victor Rivera • 24 Feb 2022
Cognitive involvement in MS – the importance 0:50
Cognitive involvement in MS – the importance
Leigh Charvet • 26 Feb 2022
An independent focal inflammation cohort – performance of the MSDA validation test algorithm 1:37
An independent focal inflammation cohort – performance of the MSDA validation test algorithm
Ferhan Qureshi • 24 Feb 2022
Metformin – a means to promote remyelination in the ageing MS population? 1:01
Metformin – a means to promote remyelination in the ageing MS population?
Jason Plemel • 25 Feb 2022
Highlights from ACTRIMS: comorbidities & paramagnetic rim lesions in MS 2:00
Highlights from ACTRIMS: comorbidities & paramagnetic rim lesions in MS
Burcu Zeydan • 24 Feb 2022
Focusing on sex and hormones in MS prognosis 1:21
Focusing on sex and hormones in MS prognosis
Burcu Zeydan • 24 Feb 2022
The unmet needs of treating patients with progressive MS 1:26
The unmet needs of treating patients with progressive MS
Jason Plemel • 25 Feb 2022
The potential of non-invasive brain stimulating therapies in negating the adverse symptoms of MS 1:10
The potential of non-invasive brain stimulating therapies in negating the adverse symptoms of MS
Leigh Charvet • 26 Feb 2022
Crucial findings in progressive MS 1:17
Crucial findings in progressive MS
Jason Plemel • 25 Feb 2022
Research developments in MOGAD 1:23
Research developments in MOGAD
Michael Levy • 25 Feb 2022
The content of VJNeurology is intended for healthcare professionals